NCT01215773View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2010

Conditions
Healthy
Interventions
DRUG

Placebo

Matching to HEA 200 mg tablet, oral administration

DRUG

BI 671800

High dose oral administration

DRUG

BI 671800

Medium dose oral administration

Trial Locations (1)

Unknown

1268.59.1 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01215773 - Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers. | Biotech Hunter | Biotech Hunter